Key result
Combination of statins with ezetimibe, bile acid sequestrants, or omega-3 fatty acids appears safe, while combining high-dose statins with niacin or fenofibrate requires caution regarding myopathy.
Why the study?
Are combination lipid-altering drug therapies safe and tolerable in patients with hyperlipidemia?
Are combination lipid-altering drug therapies safe and tolerable in patients with hyperlipidemia?
Combination therapies of statins with ezetimibe, bile acid sequestrants, or ω-3 fatty acids are generally safe, but caution is advised when combining high-dose statins with niacin or fenofibrate.
Answers are grounded in this paper and cite their sources.
May guide selective statin adjunct choice in hyperlipidemia; leaves open need for RCTs to confirm myopathy risks.
INTRODUCTION: Despite statin monotherapy, many high-risk patients are not at recommended low-density lipoprotein cholesterol goals. Moreover, these patients are also likely to exhibit an atherogenic dyslipidemia characterized by decreased high-density lipoprotein cholesterol and elevated triglycerides. As a consequence, combination lipid-altering drug therapies are frequently required to improve the lipid profile. The long-term safety and tolerability of these combination therapies are key determinants for good compliance and cardiovascular benefits. AREAS COVERED: This review summarizes the safety data published on combination drugs for the treatment of hyperlipidemia by examining the various combinations with a statin and also the other combination therapies used when statin treatment is not tolerated. The reader will gain insight into the incidence and severity of the major adverse events expected with combination therapies and the recommendations on the use of these combined treatments. A specific focus is made on muscle-related side effects. EXPERT OPINION: The existing data suggest that ezetimibe, bile acid sequestrants and ω-3 fatty acids appear unlikely to increase the risk of adverse events, particularly myopathy, when used in combination with a statin, even with a high-dose statin. Although the combination of niacin or fenofibrate with moderate-dose statins appears to be safe, prescribing a combination of these drugs with high-dose statins needs caution and requires giving careful information to the patient.
No takes yet. Share an insight, caveat, or question.
Michel Farnier (2011) conducted a review in Hyperlipidemia. Combination lipid-altering drug therapies was evaluated on Incidence and severity of major adverse events, particularly myopathy. Combination of statins with ezetimibe, bile acid sequestrants, or omega-3 fatty acids appears safe, while combining high-dose statins with niacin or fenofibrate requires caution regarding myopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: